-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Patient Advocacy
-
Patient Perspective: Exercise Prescriptions Needed for Lung Cancer Patients
Runner and patient advocate Angus Pratt says running three times a week may be the antithesis of what most people expect from a lung cancer patient, but not only is it possible, it is beneficial.
-
Words Matter: Coping with Misinformation in Healthcare
Advocate Angus Pratt explores the issues patients face while researching their disease when inaccurate and out-of-date information is everywhere.
-
Patient Advocacy in 2023: A Look Back at Advocacy Efforts, Patient Concerns
Patient research advocate Angus Pratt reflects on the past year of advocacy coverage in ILCN and how the movement has evolved in recent years.
-
Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2
In light of recent data from the study of osimertinib with or without chemotherapy, patient advocate Ivy Elkins said the results may sway some to add chemo to their first-line treatment plan. However, for others, the impact on quality of life will not be worth it.
-
Media Training Improves Advocacy Reach, Increases Lung Cancer Awareness
LungCAN Co-Chair Dusty Donaldson says training program helped just two advocates reach more than 630 million people in 32 states and five countries.
-
Artificial Intelligence in Healthcare: A Patient Perspective
When life-and-death decisions are at stake, will patients welcome AI to their care team? As part of ILCN’s series on AI in lung cancer, patient advocate Angus Pratt explores issues of trust, safety, accuracy, and more.
-
Majority of NSCLC Patients from Low Socio-Economic Areas in England Do Not Receive Novel Anti-Cancer Therapies
Despite access to free treatment within the National Health Service, patients in the most deprived areas were 55% less likely to receive targeted therapies, biologic treatments, and immunotherapy compared to residents in the least deprived areas.
-
EGFR Resisters Announce 5th Annual Research Summit
Advocacy group says its annual research events are key to its mission: Making EGFR-mutated lung cancer a manageable chronic disease.
-
The Weight of Shame
Advocate Terri Ann DiJulio knows the stigma associated with smoking must end if more lung cancer patients are to be diagnosed and treated early. The first step is talking about it.
-
Patient Perspective: ‘Scanxiety’ Triggered by Cancer, Not Scans
Patient advocate Dusty Donaldson says for most patients regular surveillance is not the problem and points out limitations of data that fail to show better outcomes with frequent scanning.